Lantheus Holdings IncLNTH
± 混在規制関連度
Lantheus withdrew and refiled its HSR pre-merger notification for the $8B Curium acquisition to give the FTC more review time, a routine antitrust step that delays but does not block the deal.
資産への影響 1
Biotech & Genomic Medicine
Lantheus Holdings Incテーマインパクト
カバレッジ外企業 1
Curium非上場± 混在
規制関連度
Curium is the target of Lantheus's $8B acquisition, whose HSR filing was withdrawn and refiled for extended FTC antitrust review, still expected to close in H1 2027.